Company Profile

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize products in the United States. The Companyâ€™s clinical-stage oncology product candidate is TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody. TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). Its clinical-stage product candidate, Envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma.

Employees

Sector

Pharmaceuticals

More about the company

24-10-10	TRACON Pharmaceuticals, Inc. announced a financing transaction	CI
24-08-13	TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-07-30	TRACON Pharmaceuticals, Inc. Announces the Appointment of Craig R. Jalbert as President, Treasurer and Secretary, and Sole Member of the Board	CI
24-07-30	TRACON Pharmaceuticals, Inc. Announces the Appointment of Craig R. Jalbert as CEO	CI
24-07-30	TRACON Pharmaceuticals Announces It Will Wind Down Operations	CI
24-07-01	TRACON Pharmaceuticals, Inc.(OTCPK:TCON) dropped from S&P TMI Index	CI
24-07-01	TRACON Pharmaceuticals to Explore Strategic Alternatives Leveraging its In-House Product Development Platform	CI
24-07-01	Tracon to Explore Strategic Alternatives After Trial Misses Target	MT
24-07-01	TRACON Pharmaceuticals Announces Termination of Envasarc Trial and Will Explore Strategic Alternatives Leveraging Its In-House Product Development Platform	CI
24-06-26	TRACON Pharmaceuticals, Inc.(OTCPK:TCON) dropped from NASDAQ Composite Index	CI
24-06-21	TRACON Pharmaceuticals, Inc. Announces Resignation of David Lazar as Chief Business Development Officer	CI
24-06-21	Top Premarket Decliners	MT
24-06-11	TRACON Pharmaceuticals, Inc. Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for Trc102, A Dna Damage Repair Inhibitor, in Recurrent Glioblastoma Patients	CI

24-03-06	HC Wainwright Adjusts Price Target on TRACON Pharmaceuticals to $6 From $7, Keeps Buy Rating	MT
23-08-21	JonesTrading Downgrades TRACON Pharmaceuticals to Hold From Buy	MT
23-08-15	Baird Trims Price Target on TRACON Pharmaceuticals to $3 From $7, Maintains Outperform Rating	MT
23-05-11	Maxim Adjusts TRACON Pharmaceuticals' Price Target to $3 From $8, Keeps Buy Rating	MT
23-05-11	Baird Trims Price Target on TRACON Pharmaceuticals to $7 From $8, Maintains Outperform Rating	MT

24-08-13	Tracon: Q2 Earnings Snapshot	AQ
24-07-30	TRACON Pharmaceuticals Announces it Will Wind Down Operations	AQ
24-07-01	TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform	AQ
24-06-12	TRACON Pharmaceuticals : Failure to Satisfy Listing Rule Form 8 K	PU
24-06-11	TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients	AQ

3 years	0		14.75
5 years	0		80.8
10 years	0		1,460

Manager	Title	Age	Since
Craig Jalbert CEO	Chief Executive Officer	65	2024-07-30
James L. Freddo CTO	Chief Tech/Sci/R&D Officer	71	2020-04-30
Brenda Marczi LAW	General Counsel	-	2021-07-19

TRACON Pharmaceuticals, Inc. Stock

Stocks

TCON

US89237H3084

Pharmaceuticals

Latest news: TRACON Pharmaceuticals, Inc.

Analysts' recommendations: TRACON Pharmaceuticals, Inc.

Press Releases: TRACON Pharmaceuticals, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: TRACON Pharmaceuticals, Inc.

Latest insider transactions

Biopharmaceuticals

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/12/24	Charles Theuer	Free	Chief Executive Officer	525,300	1.6867%
3/12/24	Scott Brown	Free	Chief Financial Officer	228,300	0.7330%
11/10/23	Opaleye Management, Inc.	Sell	Company	4,764,008	15.5180%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TRACON PHARMACEUTICALS, INC.	-26.01%	-.--%	-	-	110K
ELI LILLY AND COMPANY	+2.83%	+4.40%	+60.84%	+123.50%	1,165B
JOHNSON & JOHNSON	+3.81%	+5.66%	+38.70%	+74.91%	645B
ABBVIE INC.	+0.14%	+0.63%	+24.71%	+95.03%	504B
ROCHE HOLDING AG	-0.36%	+2.80%	+43.52%	+64.09%	380B
MERCK & CO., INC.	-1.76%	+1.41%	+68.06%	+43.41%	363B
NOVARTIS AG	-0.76%	+2.28%	+22.02%	+50.93%	297B
ASTRAZENECA PLC	-1.83%	+2.12%	+1.71%	+25.84%	269B
AMGEN INC.	+2.04%	+3.05%	+51.12%	+60.42%	237B
GILEAD SCIENCES, INC.	+2.36%	-0.11%	+29.42%	+102.04%	195B
Average	-2.81%	+2.54%	+37.79%	+71.13%	450.61B
Weighted average by Cap.	-0.52%	+3.17%	+43.00%	+82.97%